JP2019509054A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509054A5
JP2019509054A5 JP2018554653A JP2018554653A JP2019509054A5 JP 2019509054 A5 JP2019509054 A5 JP 2019509054A5 JP 2018554653 A JP2018554653 A JP 2018554653A JP 2018554653 A JP2018554653 A JP 2018554653A JP 2019509054 A5 JP2019509054 A5 JP 2019509054A5
Authority
JP
Japan
Prior art keywords
meditope
antibody
free
meditopu
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554653A
Other languages
English (en)
Japanese (ja)
Other versions
JP6983808B2 (ja
JP2019509054A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012754 external-priority patent/WO2017120599A1/en
Publication of JP2019509054A publication Critical patent/JP2019509054A/ja
Publication of JP2019509054A5 publication Critical patent/JP2019509054A5/ja
Application granted granted Critical
Publication of JP6983808B2 publication Critical patent/JP6983808B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554653A 2016-01-08 2017-01-09 自己架橋性抗体 Expired - Fee Related JP6983808B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276803P 2016-01-08 2016-01-08
US62/276,803 2016-01-08
US201662317342P 2016-04-01 2016-04-01
US62/317,342 2016-04-01
PCT/US2017/012754 WO2017120599A1 (en) 2016-01-08 2017-01-09 Self-crosslinking antibodies

Publications (3)

Publication Number Publication Date
JP2019509054A JP2019509054A (ja) 2019-04-04
JP2019509054A5 true JP2019509054A5 (enExample) 2020-02-20
JP6983808B2 JP6983808B2 (ja) 2021-12-17

Family

ID=59274084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554653A Expired - Fee Related JP6983808B2 (ja) 2016-01-08 2017-01-09 自己架橋性抗体

Country Status (8)

Country Link
US (1) US11459397B2 (enExample)
EP (1) EP3399992A4 (enExample)
JP (1) JP6983808B2 (enExample)
KR (1) KR20180098672A (enExample)
CN (1) CN108712908A (enExample)
AU (1) AU2017205343A1 (enExample)
CA (1) CA3010632A1 (enExample)
WO (1) WO2017120599A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190111149A1 (en) * 2016-02-02 2019-04-18 Meditope Biosciences, Inc. Anti-egfr antibody drug conjugate
AU2019234468A1 (en) * 2018-03-12 2020-10-01 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
CN109521192B (zh) * 2018-11-27 2021-07-13 柏荣诊断产品（上海）有限公司 一种提高胶乳比浊试剂检测灵敏度的方法
KR20220078665A (ko) * 2019-10-10 2022-06-10 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 다중특이적 면역 세포 인게이저를 발현하는 종양용해 바이러스
EP4025250A4 (en) * 2019-10-12 2024-01-17 Bio-Thera Solutions, Ltd. FORMULATION OF ANTI-CD20 ANTIBODIES AND USE OF ANTI-CD20 ANTIBODIES FOR THE TREATMENT OF CD20-POSITIVE DISEASES
KR20220110556A (ko) * 2019-12-06 2022-08-08 아지노모토 가부시키가이샤 생리 활성을 갖는 펩타이드의 제조 방법 및 단쇄 링커를 포함하는 펩타이드
US20230119066A1 (en) * 2020-03-23 2023-04-20 Bristol-Myers Squibb Company Anti-ccr8 antibodies for treating cancer
US20230372522A1 (en) * 2020-09-29 2023-11-23 Kunming Sinoway Natural Pharmaceuticals Co., Ltd. Humanized anti-cd22 recombinant immunotoxin and application thereof
CN112661828B (zh) * 2021-01-15 2022-04-01 武汉大学 一种突触素的抗原肽及其抗体与应用
EP4282873A4 (en) * 2021-01-22 2024-11-27 Ajinomoto Co., Inc. METHOD FOR SCREENING DIMERIZED CYCLIC PEPTIDES
CA3212386A1 (en) * 2021-03-18 2022-09-22 Alessandro ARCOVITO Ferritin variants with increased stability and complexation ability
CN115677856B (zh) * 2021-07-29 2023-11-28 东莞市朋志生物科技有限公司 抗人IgM抗体及其应用
JP2024025400A (ja) * 2022-08-12 2024-02-26 浜松ホトニクス株式会社 膜貫通タンパク質を標的オルガネラに局在化させるためのペプチドリンカー及び局在化方法並びに局在化する融合タンパク質

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124912T2 (de) * 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
JP2008507292A (ja) * 2004-07-26 2008-03-13 アステリオン・リミテッド リンカー
US20140127200A1 (en) * 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
AU2011312106B8 (en) * 2010-10-08 2017-09-14 City Of Hope A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CN114634572A (zh) * 2011-10-10 2022-06-17 希望之城公司 中间位和中间位结合抗体及其用途
US9428553B2 (en) * 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CA2962957A1 (en) * 2014-10-02 2016-04-07 City Of Hope Multivalent meditopes, meditope-binding antibodies and uses thereof
AU2016265845B2 (en) * 2015-05-15 2020-10-08 City Of Hope Chimeric antigen receptor compositions
US20190111149A1 (en) * 2016-02-02 2019-04-18 Meditope Biosciences, Inc. Anti-egfr antibody drug conjugate

Similar Documents

Publication Publication Date Title
JP2019509054A5 (enExample)
JP2020180158A5 (enExample)
JP2018508483A5 (enExample)
JP2020062036A5 (enExample)
JP2014526898A5 (enExample)
JP2019147801A5 (enExample)
JP2017529067A5 (enExample)
JP2018537415A5 (enExample)
JP2017029157A5 (enExample)
JP2018108081A5 (enExample)
JP2018521638A5 (enExample)
JP2016536322A5 (enExample)
JP2020500525A5 (enExample)
JP2010535012A5 (enExample)
JP2010526028A5 (enExample)
JP2017504578A5 (enExample)
JP2018527919A5 (enExample)
JP2018517431A5 (enExample)
RU2018112861A (ru) Стабильные антитела, связывающиеся с несколькими антигенами
WO2016207304A8 (en) Monoclonal anti-il-1racp antibodies
JP2013538057A5 (enExample)
RU2016106577A (ru) САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII
HRP20190472T1 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
JP2009505676A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение